Skip to main content

Table 2 Adherence with local guidelines

From: In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis

Diagnosis confirmed clinically and biochemically

100%

Removal of potential culprit drugs

100%

Exclusion of adrenal / thyroid pathology

100%

Documentation of fluid balance status and charts

92%

Documentation of 48 h fluid restriction prior to starting Tolvaptan

96%

Tolvaptan initiation according to Trust policy

96%

Na level monitoring before/after initiation as per recommendations

96%